Key Takeaways
- Research led by Lu at Harvard shows promise in age-reversal techniques, particularly in repairing optic nerves.
- A nearly identical gene therapy has begun human clinical trials for glaucoma.
- The technique, called ER-100, retains much of its original form since its development as a student project by Lu.
Revolutionary Advances in Rejuvenation Science
Lu has made significant strides in the field of rejuvenation science, particularly in eye research. In 2018, while pursuing a PhD at Harvard Medical School, Lu utilized a groundbreaking age-reversal method known as reprogramming to effectively repair damaged optic nerves in mice. After inflicting nerve damage, which resulted in blindness, he injected the affected cells with a gene therapy designed to restore their youthful functionality. Remarkably, just 16 days later, the optic nerves began to regenerate, displaying new growth under a microscope.
Lu’s research has garnered enthusiasm amongst scientists and the public alike. David Sinclair, a prominent longevity researcher and director of Lu’s laboratory, recalls receiving a text from Lu containing images of the results. Sinclair proclaimed, “I see the future,” highlighting the potential impact of these findings.
The mice subjected to this innovative treatment not only experienced nerve regeneration, but they also regained their vision, as confirmed in tests involving rotating light bars. This year, the gene therapy conceived by Lu transitioned into human clinical trials, marking a significant moment in medicinal science. On June 9, Life Biosciences, a startup co-founded by Sinclair and where Lu holds a small equity stake, reported that the therapy had been injected into the eye of a glaucoma patient. The uproar surrounding this clinical trial has been substantial, with major media outlets and social media confirming its groundbreaking potential; headlines suggest it could “change humanity” and some have dubbed it “the fountain of youth.”
What makes this development particularly notable is the therapy’s continuity from its initial conception to its current application. Sinclair emphasized that the treatment, now known as ER-100, has undergone minimal alterations since its inception, showcasing the robustness of Lu’s research.
The technique itself—reprogramming—mimics a natural process observed in embryos, where inherited DNA undergoes a resetting process, contributing to youth. The groundwork for this form of reprogramming was established in 2006 by Japanese researchers, who demonstrated that introducing four specific genes, known collectively as OSKM, could revert adult cells to a pluripotent stem cell state. This suggests that even a cell from a centenarian can behave as if it were derived from a youthful embryo when treated with these genes.
With human trials underway for the treatment originally conceived in a university lab, the outlook for age-reversal therapies seems promising. The implications for regenerative medicine, particularly for age-related conditions, could be numerous, transforming lives and potentially allowing for enhanced longevity. As the world closely watches the outcomes, Lu’s pioneering work stands at the forefront of a rapidly evolving field that merges genetics with the quest for extended youth.
The content above is a summary. For more details, see the source article.